Baxter International (BAX)
(Delayed Data from NYSE)
$21.96 USD
+0.20 (0.92%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $22.15 +0.19 (0.87%) 7:58 PM ET
4-Sell of 5 4
A Value D Growth B Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Baxter International Inc. has a PEG ratio of 0.64 compared to the Medical - Products industry's PEG ratio of 2.14.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BAX 21.96 +0.20(0.92%)
Will BAX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BAX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BAX
Baxter International (BAX) Misses Q2 Earnings and Revenue Estimates
BAX Stock Falls Following Q2 Earnings & Sales Miss, '25 EPS View Down
BAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Baxter (BAX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Stay Ahead of the Game With Baxter (BAX) Q2 Earnings: Wall Street's Insights on Key Metrics
InMode (INMD) Q2 Earnings and Revenues Beat Estimates
Other News for BAX
Notable healthcare headlines for the week: Trump’s ultimatum to big pharma, Novo Nordisk, UnitedHealth and Moderna in focus
Trump imposes new tariffs, Apple reports Q3 beat: Morning Buzz
Significant Option Activity in Baxter (BAX) Drives Market Interest
BAX: Wells Fargo Lowers Price Target to $24, Maintains Equal-Weight Rating | BAX Stock News
Avis Budget downgraded, Sprouts upgraded: Wall Street's top analyst calls